Inion explores BMP-4 product for preventing abnormal bone growth:
This article was originally published in Clinica
Executive Summary
Finnish orthopaedics firm Inion has received a patent in Finland covering a genetically modified form of the bone morphogenetic protein BMP-4 that could prevent the abnormal formation of bone in non-bony tissues, a condition known as heterotopic ossification (HO). HO is observed in up to 50% of patients undergoing spinal fusion surgery and in 71% of those receiving total hip replacements, said the Tampere firm. The company, which has also had a US patent issued for its BMP-4 technology, said it is exploring routes to market the product, which may involve an out-licensing deal to commercialise the intellectual property with a partner. There is significant market potential for a product that reduces the incidence of HO in a more cost-effective form, said the firm.